DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
0.00%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.96 4.50 −5.33%
Market cap
$31.5B
P/E
32.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by regions, and margins
United States 3,335 71.53%
International 1,327 28.47%
Gross margin 60.10%
Operating margin 19.56%
Pre-tax margin 23.35%

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014
United States 3,335 2,890 2,625 2,142 1,849 1,510 1,162 818 596 498 347 224
International 1,327 1,143 997 768 599 417 315 213 122 76 55 35
Revenue 4,662 4,033 3,622 2,910 2,449 1,927 1,476 1,032 719 573 402 259

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.